硝基咪唑类PET肿瘤乏氧显像剂的研究总结和展望  

Progress of Tumor Hypoxia Imaging Agents Containing Nitroimidazole for Positron Emission Tomography

作　　者：于倩[1] 王振光[1] 陈成成[1] 刘思敏[1] 石彬[1] 

机构地区：[1]青岛大学附属医院PET/CT中心,山东青岛266000

出　　处：《核化学与放射化学》2015年第6期385-392,共8页Journal of Nuclear and Radiochemistry

摘　　要：乏氧显像剂能选择性的滞留在乏氧组织或细胞中。随着正电子发射计算机断层显像(PET)技术的发展,PET肿瘤乏氧显像可无创性评估实体瘤的乏氧状态,对肿瘤的治疗指导、疗效评价和预后判断具有重要的临床应用价值。^(18)F-硝基咪唑(^(18)F-FMISO)是目前广泛用于临床研究的硝基咪唑类乏氧显像剂,然而其存在某些缺点,新的硝基咪唑类乏氧显像剂正在广泛研究。本文就近年来正电子核素标记的硝基咪唑类肿瘤乏氧显像剂的研究进展进行简要概述。Hypoxia imaging agents can selectively accumulate in hypoxic tissues or cells. With the advance of PET imaging technique, tumor hypoxia imaging for PET has great clini- cal value for guiding tumor therapy, evaluating therapeutic efficacy and estimating progno- sis. 18 F-FMISO is the widely studied PET tumor hypoxia imaging agent containing nitroimid- azole, but it still has some disadvantages. Up to now, more and more novel PET tumor hypoxia imaging agents containing nitroimidazole are under investigation. This review briefly introduced some the research progress of tumor hypoxia imaging agents containing nitroimid-azole for PET.

关 键 词：肿瘤乏氧 PET 硝基咪唑类乏氧显像剂 

分 类 号：R817[医药卫生—影像医学与核医学]